Hart et al. (2017) have generated a panel of IgA antibodies targeting five different tumor antigens (MUC1, HER2, EGFR, TF, and CD20) by using human myelogenous leukemia-derived GlycoExpress (GEX) cell lines. This evidence concerns the gene CD79A and neoplasm.